These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1301 related articles for article (PubMed ID: 15476679)

  • 21. Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.
    White JB; Thompson WJ; Pittler SJ
    Mol Vis; 2004 Oct; 10():738-49. PubMed ID: 15480303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
    Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
    Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
    Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
    Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
    Xin ZC; Kim EK; Lin CS; Liu WJ; Tian L; Yuan YM; Fu J
    Asian J Androl; 2003 Mar; 5(1):15-8. PubMed ID: 12646997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells.
    Ashikaga T; Strada SJ; Thompson WJ
    Biochem Pharmacol; 1997 Nov; 54(10):1071-9. PubMed ID: 9464449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
    Shin HJ; Kim HJ; Kwak JH; Chun HO; Kim JH; Park H; Kim DH; Lee YS
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2313-6. PubMed ID: 12161123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes.
    Rivet-Bastide M; Vandecasteele G; Hatem S; Verde I; Bénardeau A; Mercadier JJ; Fischmeister R
    J Clin Invest; 1997 Jun; 99(11):2710-8. PubMed ID: 9169501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
    Qiu Y; Kraft P; Lombardi E; Clancy J
    J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
    Makhay MM; Houslay MD; O'Donnell JM
    Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
    Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
    Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig.
    Johnson WB; Katugampola S; Able S; Napier C; Harding SE
    Life Sci; 2012 Feb; 90(9-10):328-36. PubMed ID: 22261303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
    Ellis JL; Conanan ND
    J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of visnagin on cyclic nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction.
    Duarte J; Lugnier C; Torres AI; Pérez-Vizcaino F; Zarzuelo A; Tamargo J
    Gen Pharmacol; 1999 Jan; 32(1):71-4. PubMed ID: 9888257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 37. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung.
    Haynes J; Killilea DW; Peterson PD; Thompson WJ
    J Pharmacol Exp Ther; 1996 Feb; 276(2):752-7. PubMed ID: 8632346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
    Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
    Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
    Murray F; MacLean MR; Pyne NJ
    Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.